6. STOCKHOLDERS' EQUITY	3 Months Ended
Mar. 31, 2019
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 6 – STOCKHOLDERS’ EQUITY Preferred Stock At March 31, 2019 and December 31, 2018, the number of authorized shares of our preferred stock was 10,000,000. The par value of the preferred stock is $0.0001. At March 31, 2019 and December 31, 2018, there is one share of Series A Preferred Stock outstanding. Common Stock As of March 31, 2019, the number of authorized shares of our common stock was 8,000,000,000. The par value of the common stock is $0.0001. As of March 31, 2019, we issued 3,200,000 shares of common stock to a consultant of the Company. The shares were issued at fair market value of approximately $1,000 on the date of the issuance. As of March 31, 2019, we issued 26,143,791 shares of common stock to CEO Kevin Schewe as he converted loans into shares of common stock as allowed under an agreement he has with us as discussed in Note 5. As of March 31, 2019 we issued 775,984,665 shares of common stock to CEO Kevin Schewe for the purchase of Elite Therapeutics. As of March 31, 2019, there were 4,732,073,007 shares of common stock issued and 4,632,073,007 shares of common stock outstanding.

6. STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2019

NOTE 6 – STOCKHOLDERS’ EQUITY

Preferred Stock

At March 31, 2019 and December 31, 2018, the number of authorized shares of our preferred stock was 10,000,000. The par value of the preferred stock is $0.0001.

At March 31, 2019 and December 31, 2018, there is one share of Series A Preferred Stock outstanding.

Common Stock

As of March 31, 2019, the number of authorized shares of our common stock was 8,000,000,000. The par value of the common stock is $0.0001.

As of March 31, 2019, we issued 3,200,000 shares of common stock to a consultant of the Company. The shares were issued at fair market value of approximately $1,000 on the date of the issuance.

As of March 31, 2019, we issued 26,143,791 shares of common stock to CEO Kevin Schewe as he converted loans into shares of common stock as allowed under an agreement he has with us as discussed in Note 5.

As of March 31, 2019 we issued 775,984,665 shares of common stock to CEO Kevin Schewe for the purchase of Elite Therapeutics.

As of March 31, 2019, there were 4,732,073,007 shares of common stock issued and 4,632,073,007 shares of common stock outstanding.

VIASPACE Inc. 10-Q